Geistlich unveils vallos – a new demineralized allograft that sets the pace for regeneration

2022-11-08

This Geistlich Select product line brings an added confidence to regenerative procedures Introducing vallos from Geistlich North America. (Credit: PR Newswire/ Geistlich Pharma North America, Inc.) Geistlich Pharma North America Inc. is setting the pace for expanded treatment options with the introduction of vallos, our first demineralized allograft. With two formulations for treatment flexibility, vallos granules are ideally suited for smaller routine defects while vallos f fibers are designed for larger more complex defects. This Geistlich Select product line brings an added confidence to regenerative procedures, with: Verified osteoinductive potential in every lot Consistent product quality Proven regenerative capacity by exhibiting all five elements of bone formation1 Vital bone after 18-20 weeks Geistlich Select: Geistlich is proud of the quality and safety of its products and consistently employs rigorous scientific validation and strict manufacturing processes. Extensive research and collaboration have created a partnership to bring you select allograft materials designed for clinical versatility and success. Demineralized vallos and vallos f offer clinicians more options to enhance their ability to manage a variety of clinical indications and are the first products to become part of the Geistlich Select family. “We are excited to bring these first allograft innovations to clinicians, which provides them with new options for their regenerative procedures. We will be expanding our allograft product line with additional solutions in the near future, as part of our Geistlich Select family,” said Les Burrows, General Manager of Geistlich Pharma North America. Source: Company Press Release

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Geistlich